Details of the Drug

General Information of Drug (ID: DMZDTYD)

Drug Name

Bezuclastinib

Synonyms

Bezuclastinib; CGT9486; PLX-9486; 2ROQ545LAG; PLX9486; CGT-9486; 1616385-51-3; UNII-2ROQ545LAG; PLX 9486 [WHO-DD]; 4,5-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-3-carboxamide; 3,4-Dimethyl-N-(2-phenyl-1H-pyrrolo(2,3-b)pyridin-5-yl)-1H-pyrazole-5-carboxamide; 3,4-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-5-carboxamide; Bezuclastinib [WHO-DD]; BEZUCLASTINIB [INN]; BEZUCLASTINIB [USAN]; CHEMBL5095229; SCHEMBL15824576; GTPL11868; NVSHVYGIYPBTEZ-UHFFFAOYSA-N; BDBM392363; GLXC-26827; EX-A5975; US10301280, Compound P-2007; US10301280, Compound P-2164; MS-24986; HY-145557; CS-0376032; 1H-Pyrazole-3-carboxamide, 4,5-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-; 3,4-dimethyl-N-(2-phenyl-1H- pyrrolo[2,3-b]pyridin-5-yl)-1H- pyrazole-5-carboxamide; WEJ

Indication

Disease Entry	ICD 11	Status	REF
Gastrointestinal stromal tumour	2B5B	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C19H17N5O
Canonical SMILES: CC1=C(NN=C1C(=O)NC2=CN=C3C(=C2)C=C(N3)C4=CC=CC=C4)C
InChI: InChI=1S/C19H17N5O/c1-11-12(2)23-24-17(11)19(25)21-15-8-14-9-16(22-18(14)20-10-15)13-6-4-3-5-7-13/h3-10H,1-2H3,(H,20,22)(H,21,25)(H,23,24)
InChIKey: NVSHVYGIYPBTEZ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 75593308
TTD ID: DLC7Y9

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
KIT D816V mutant (KIT D816V)	TTGTJB2	KIT_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05208047) A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Cogent Biosciences